Phase IV studies: Pioneering approaches are re-engineering processes, timelines and costs
Phase IV is in a state of flux. New digital methods are on trial, there’s an explosion of data sources, and more questions about the level of evidence needed are being asked. At the same time, drug companies are trying to control costs. What’s the best way forward?
If you want to design and carry out more effective Phase IV trials studies, you need to find out what lessons have already been learned about lean protocol design, opportunities for savings and considering the patient voice, from companies like Genentech and Sanofi (see the full list). You'll also get fresh insights into how key studies have performed, and clear pointers to what could be improved.Request Sample Pages
- Separate standard operating procedures are needed for Phase IV studies
- Planning should start earlier for Phase IV studies to improve their effectiveness and business value
- Research objectives need to be clear and focussed to avoid waste of resources
- New protocols and platforms are beginning to impact on study design, data collection and methodologies
- Potential for significant savings exists but these won't be realised until confidence in the methodologies improves
- Including the patient's voice is easier – but there are still careful considerations required
- Key real-world drug-use learnings can result from new approaches
Key Issues Explored
- When should you start considering Phase IV studies in your testing processes?
- How patient insights and various customer needs can result in benefits for all stakeholders
- Insight into ground-breaking trials and lessons learned so far in 2 key case studies including the Salford Lung Study
- The new integrated evidence pathways gaining ground and what their true long-term value is likely to be
- The growth and use of databases by researchers
- How new partnerships forged by drug companies to progress studies are working in practice
- Concerns around quality and reliability of evidence gathered
Who needs this report?
- Anyone involved in designing, recruiting, executing or analysing Phase IV studies – to see how they can be improved
- Regulatory teams – to gain insights into current and new practices
- Executives who want to understand evolution of best practice and explore potential cost savings
- Data managers at pharma companies, CROs and associated organisations
- Manufacturers and programmers of wearable medical and health devices (such as FitBit) – to understand potential future applications
- Patient engagement teams – to understand new ways of involving patients
- Charlie Barr, Group Medical Director and Head, Evidence Science and Innovation, Genentech
- Dr Nadir Ammour, eClinical Director, Sanofi
- Chris Liebman, Vice President, HEOR, Global Market Access, Biogen
- Dr Shontelle Dodson, Head of Medical Affairs Excellence, Astellas US
- Dr David Leather, Medical Affairs Leader in the Respiratory Franchise, GlaxoSmithKline
- Dr Tobias Gantner, Director Health Economics & Market Access, Janssen Germany
- Jeff Trotter, co-founder and managing director, Continuum Clinical
- Mike Minor, Senior Vice President & Global Head Operations and Strategic Planning, Peri-Approval & Observational Research, ICON
- Lynn Okamoto, Executive Vice-President for Late Stage research, InVentiv Health
- Kai Langel, Director of patient solutions, e-clinicalhealth
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Dossier reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today.
Questions? Please contact us at firstname.lastname@example.org.